X
Novartis trumpets long-term data for Cosentyx in psoriasis
https://pharmaphorum.com/news/novartis-trumpets-long-term-data-cosentyx-psoriasis/
dermatology
Sanofi looks to Dupixent as diabetes sales plummet
Dupixent off to strong start after US launch
Sanofi showcases eczema data ahead of EU decision
Dupixent predicted to be blockbuster for Sanofi
Roche sells rights to troubled asthma and eczema drug
Dermira will focus on development in eczema.
J&J’s psoriasis drug faces crowded market after US approval
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
Novartis’ psoriasis drug gets label boost
New label shows Cosentyx is superior to J&J’s rival in long-term.
Cardiome antibiotic could reduce pressure on NHS
Xydalba allows patients to be treated and quickly discharged.
Valeant’s Siliq price undercuts rivals to offset black box warning
Siliq will be cheaper than rivals from Novartis and Eli Lilly.
FDA approves two biggest new drugs of 2017
Sales of MS and eczema drugs could top $4bn by 2022